Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)

Branch of Organ Transplantation of Chinese Medical Association

doi:10.3969/j.issn.1674-7445.2021.01.002

Volume 12 Issue 1

Jan. 2021

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2021 > 12(1): 8-14, 28

Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. ORGAN TRANSPLANTATION, 2021, 12(1): 8-14, 28. doi: 10.3969/j.issn.1674-7445.2021.01.002

Citation:

PDF( 854 KB)

Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)

doi: 10.3969/j.issn.1674-7445.2021.01.002

Branch of Organ Transplantation of Chinese Medical Association^,

Xijing Hospital of Air Force Medical University, Xi'an 710032, China

More Information

Corresponding author: Tao Kaishan, Email: taokaishan0686@163.com
Received Date: 2020-11-18
Available Online: 2021-01-19
Publish Date: 2021-01-19

Abstract

Abstract

The liver is an "immune-privileged organ". The incidence and severity of acute rejection after liver transplantation are significantly lower than those after the transplantation of other organs. However, postoperative rejection is still relatively common, and standardized immunosuppressive therapy is the key to guarantee the efficacy of transplantation. To further standardize the immunosuppressive therapy and diagnosis and treatment of rejection after liver transplantation, Branch of Organ Transplantation of Chinese Medical Association organized liver transplant experts to summarize the latest research progress at home and abroad, integrate international guidelines and clinical practice and formulate the "Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)" based upon the application principle and common regime of immunosuppressant, as well as diagnosis and treatment of various types of rejection after liver transplantation.
- Liver transplantation,
- Immunosuppressive therapy,
- Transplantation immunity,
- Rejection

FullText(HTML)

References(20)

References

[1]	HALLIDAY N, WESTBROOK RH. Liver transplantation: post-transplant management[J]. Br J Hosp Med (Lond), 2017, 78(5):278-285. DOI: 10.12968/hmed.2017.78.5.278.
[2]	SHAKED A, DESMARAIS MR, KOPETSKIE H, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation[J]. Am J Transplant, 2019, 19(5):1397-1409. DOI: 10.1111/ajt.15205.
[3]	JUCAUD V, SHAKED A, DESMARAIS M, et al. Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients[J]. Hepatology, 2019, 69(3):1273-1286. DOI: 10.1002/hep.30281.
[4]	GUO T, LEI J, GAO J, et al. The hepatic protective effects of tacrolimus as a rinse solution in liver transplantation: a Meta-analysis[J]. Medicine (Baltimore), 2019, 98(21): e15809. DOI: 10.1097/MD.0000000000015809.
[5]	RAYAR M, TRON C, LOCHER C, et al. Tacrolimus concentrations measured in excreted bile in liver transplant recipients: the STABILE study[J]. Clin Ther, 2018, 40(12):2088-2098. DOI: 10.1016/j.clinthera. 2018.10.015.
[6]	SALIBA F, ROSTAING L, GUGENHEIM J, et al. Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: a randomized, multicenter study[J]. Transplantation, 2016, 100(8):1705-1713. DOI: 10.1097/TP.0000000000001228.
[7]	GRIGG SE, SARRI GL, GOW PJ, et al. Systematic review with Meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019, 49(10):1260-1273. DOI: 10.1111/apt.15253.
[8]	JUNG DH, TAK E, HWANG S, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018, 24(7):932-945. DOI: 10.1002/lt.25191.
[9]	PERITO ER, MARTINEZ M, TURMELLE YP, et al. Posttransplant biopsy risk for stable long-term pediatric liver transplant recipients: 451 percutaneous biopsies from two multicenter immunosuppression withdrawal trials[J]. Am J Transplant, 2019, 19(5):1545-1551. DOI: 10.1111/ajt.15255.
[10]	CASTEDAL M, SKOGLUND C, AXELSON C, et al. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation[J]. Scand J Gastroenterol, 2018, 53(6):741-747. DOI: 10.1080/00365521.2018.1463390.
[11]	KOO J, WANG HL. Acute, chronic, and humoral rejection: pathologic features under current immunosuppressive regimes[J]. Surg Pathol Clin, 2018, 11(2):431-452. DOI: 10.1016/j.path.2018.02.011.
[12]	AIBARA N, OHYAMA K, HIDAKA M, et al. Immune complexome analysis of antigens in circulating immune complexes from patients with acute cellular rejection after living donor liver transplantation[J]. Transpl Immunol, 2018, 48:60-64. DOI: 10.1016/j.trim.2018.02.011.
[13]	LO RC, CHAN KK, LEUNG CO, et al. Expression of hepatic progenitor cell markers in acute cellular rejection of liver allografts-an immunohistochemical study[J]. Clin Transplant, 2018, 32(3):e13203. DOI: 10.1111/ctr.13203.
[14]	LEE M. Antibody-mediated rejection after liver transplant[J]. Gastroenterol Clin North Am, 2017, 46(2): 297-309. DOI: 10.1016/j.gtc.2017.01.005.
[15]	RODRÍGUEZ-PERÁLVAREZ M, RICO-JURI JM, TSOCHATZIS E, et al. Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal[J]. Transpl Int, 2016, 29(9):961-973. DOI: 10.1111/tri.12737.
[16]	MCALISTER VC. Anti-donor immunoglobulin G subclass in liver transplantation[J]. Hepatobiliary Surg Nutr, 2019, 8(2):125-128. DOI: 10.21037/hbsn.2018.12.09.
[17]	JADLOWIEC CC, TANER T. Liver transplantation: current status and challenges[J]. World J Gastroenterol, 2016, 22(18):4438-4445. DOI: 10.3748/wjg.v22.i18.4438.
[18]	FENG S, BUCUVALAS JC, DEMETRIS AJ, et al. Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants[J]. Gastroenterology, 2018, 155(6):1838-1851. DOI: 10.1053/j.gastro.2018.08.023.
[19]	BITAR C, OLIVIER K, LEE C, et al. Acute graft-vs-host disease following liver transplantation[J]. Cutis, 2019, 103(6):E8-E11.
[20]	马明, 蒋文涛.肝移植术后移植物抗宿主病[J/CD].实用器官移植电子杂志, 2014, 2(4): 249-252. DOI: 10.3969/j.issn.2095-5332.2014.04.012. MA M, JIANG WT. Graft versus host disease after liver transplantation[J/CD]. Prac J Organ Transplant(Electr Vers), 2014, (4): 249-252. DOI: 10.3969/j.issn.2095-5332.2014.04.012.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1179) PDF downloads(348)

Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)

doi: 10.3969/j.issn.1674-7445.2021.01.002

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)

doi: 10.3969/j.issn.1674-7445.2021.01.002

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content